Insights & Resources

As risk evolves, life science companies must adapt valuation methods. Learn to better align risk, value and strategy in your decision-making process.

The DOJ’s updated compliance guidelines require proactive AI risk management. Take steps to ensure your company meets the standards.

J.P. Morgan's Q1 2025 biopharma and medtech reports reveal larger deals, global growth and financial strategies shaping the life sciences industry.

Explore how proposed Medicaid cuts could impact health care valuations, reimbursement models and financial stability across various provider segments.

Within the changing landscape of educational technology, schools face new risk factors that affect students, faculty and administrators.

Learn how financial institutions can manage third-party risks, protect customer trust and minimize disruptions from critical service outages.

The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.

Companies looking to transform their operations through AI will need to guard against risk from vendors without a SOC 2 report. Learn more here.

The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.

The biopharma industry has experienced a resurgence the first part of 2024. J.P. Morgan’s Q2 report shares critical insights into the future of the industry.

Dashboards are catalysts for decision-making and operational excellence when businesses incorporate user-centric design and include key insights and alerts.

PCI DSS sets the standard for payment card security in higher education detailing compliance levels, reporting requirements and strategies to protect data.